Since its creation by Amanda Feilding in 1998, the Beckley Foundation has been at the forefront of global drug policy reform and scientific research into psychoactive substances. We collaborate with leading scientific and political institutions worldwide to design and develop ground-breaking research and global policy initiatives.
The Beckley Foundation’s purpose is two-fold:
Through the Scientific Programme, we collaborate with leading experts and institutions to design, initiate, and direct scientific research projects, including clinical trials. The studies focus on cannabis, MDMA, and psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT), and explore how these substances act upon the human brain, using the latest developments in neuroscience and brain imaging technology. The purpose of the research is to increase our scientific understanding of consciousness itself, and to explore new avenues for treatment and well-being.
Through the Policy Programme, we collaborate with a network of political leaders and drug policy analysts to develop evidence-based global drug policies. Our policy initiatives open up discussion on taboo issues surrounding the complex subject of drug policy, and they explore new regulatory models which aim to reduce the disastrous collateral harms caused by the policies of prohibition.
Psilocybin for Depression
Type of publication